Vor Biopharma (NASDAQ:VOR) Coverage Initiated by Analysts at Jefferies Financial Group

Research analysts at Jefferies Financial Group started coverage on shares of Vor Biopharma (NASDAQ:VOR) in a note issued to investors on Monday. The firm set a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 245.30% from the stock’s previous close.

VOR has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Wells Fargo & Company began coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Citigroup started coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They set a “buy” rating and a $50.00 target price for the company. JPMorgan Chase & Co. dropped their target price on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Finally, TD Cowen began coverage on shares of Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.89.

Vor Biopharma Price Performance

Vor Biopharma stock opened at $14.48 on Monday. The stock’s 50 day moving average is $14.21 and its 200 day moving average is $18.00. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80. The firm has a market cap of $150.74 million, a P/E ratio of -0.04 and a beta of 1.99.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. Jane Street Group LLC bought a new position in Vor Biopharma during the first quarter worth $140,000. XTX Topco Ltd bought a new position in Vor Biopharma during the second quarter worth $66,000. Ariose Capital Management Ltd acquired a new stake in Vor Biopharma in the third quarter worth $5,368,000. Finally, BNP Paribas Financial Markets grew its holdings in Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares during the period. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).